Aspectos farmacológicos de las anfetaminas
Keywords:
Anfetaminas, éxtasis, dopamina, serotonina, neurotoxicidadAbstract
El amplio grupo de sustancias que componen los derivados de la estructura fenilisopropilamina se encuentra en unestado de continua renovación debido al auge del consumo y tráfico ilícito de drogas como el éxtasis (MDMA), MDA,STP, DOI, etc... El estudio de su mecanismo de acción implica la participación de neurotransmisores como Dopamina,Serotonina y Catecolaminas, con un complejo comportamiento que da lugar a una difícil interpretación de losmúltiples efectos aparecidos durante su consumo. Así mismo, los derivados anfetamínicos que se conservan en elarsenal terapéutico con fines anorexígenos, presentan todas las propiedades estimulantes de la molécula inicial, conel mismo riesgo implícito que cualquiera de las de tráfico ilegal.Downloads
References
Alis, R.M. (1996) Drogas de diseño: Nuevas tendencias en el tráfico ilícito de Baleares. Farmacéuticos. 15-20.
Bagozi, F. (1996) Generazione in ecstasy. Ed. Grupo Abele. Torino.
Bobes, J.; Lorenzo, P.; Sáiz, P.A. (1998) Éxtasis (MDMA): Un abordaje comprehensivo. Masson. Madrid.
Camí, J.; Laporte, J.; Gutierrez, R.; Laporte, J.R. (1977) Estudio de los preparados que contienen anfetaminas existentes en el mercado farmacéutico nacional. Med. Clin. (Barc.), 68: 57-62
Colado, M.I. (1998) Neurotoxicidad inducida por MDMA y su prevención farmacológica. En Bobes, J.; Lorenzo, P.; Sáiz, P.A. Éxtasis (MDMA): Un abordaje comprehensivo. Masson. Madrid. pp 41-72.
Colado, M.I.; Lorenzo, P. (1995) MDMA (Extasis): Farmacología y Toxicología. En Bobes, J. Extasis aspectos Farmacológicos, psiquiátricos y médico-legales. Citrán. Barcelona. pp 1-46.
Colado, M.I.; Granados, R.; O’Shea, E.; Esteban, B.; Green, A.R. (1999) The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, «eve») on body temperature and long term degeneration of 5-HT neurones in brain: a comparison with MDMA («Ecstasy»). Pharmacol. Toxicol. 84, 261-266.
Commins, D.L.; Axt, K.J.; Vosmer, G.; Seiden, L.S. (1987) Endogenously produced 5,6-hydroxytryptamine may mediate the neurotoxic effects of parachloroamphetamine . Brain Res. 419, 253-261
Estañ, L.; Alós, M.; Villar, V.M. (1996) Concepto y clasificación de las drogas de diseño. Farm. Clin. 13:42-54
Esteban, J.M. (1996) Alucinógenos: ¿Regreso al futuro?. Farmacéuticos. 21-31.
Flórez, J. (1997) Farmacología humana. 3ª ed. Masson, S.A., Madrid.
Freo, U. (1996) Cerebral metabolic effects of serotonin drugs and neurotoxins. Life Sci. 59, 877-891.
Gamella, J.F.; Álvarez, A. (1997) Drogas de síntesis en España. Patrones y tendencias de adquisición y consumo. Ed. Doce Calles, S.L. Ministerio del Interior. Delegación del Gobierno para el Plan Nacional sobre Drogas.
Goodman y Gilman (1996) Las bases farmacológicas de la terapéutica. Ed by Hardman, J.G.; Limbird, L.E. 8ª edición. McGraw-Hill interamericana. México.
González, F.J.; Meyer, U.A. (1991) Molecular genetics of the debrisoquin-sparteine polymorphism. Clin. Pharmacol. Ther. 50, 233-238.
Gore, S.M. (1999) Fatal uncertainty: death-rate from use of ectasy or heroin. Lancet, 354, 1265-1266.
Kalivas, P.W. (1995) Interaction between dopamine and excitatory amino acids in behavioral sensibilization to phychostimulants. Drug Alcohol Depend. 37, 95-100.
Liang, N.Y.; Rutlege, C.O. (1982) Comparison of the release of (H3)dopamine from isolated striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem. Pharmacol. 31, 983-992.
Lorenzo, P. (1998) MDMA y otras feniletilaminas. Farmacología y toxicología general. En Bobes, J.; Lorenzo, P.; Sáiz, P.A. Extasis (MDMA): Un abordaje comprehensivo. Masson. Madrid. pp 15-39.
Marek, G.J.; Aghajanian, G.K. (1996) LSD and the phenethylamine allucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J. Pharmacol. Exp. Ther. 278, 1373-82.
Mark, E.J.; Patalas, E.D.; Chang, H.T.; Evans, E.J.; Kessler, S.C. (1997) Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N. Eng. J. Med., 337, 602-606.
Marona-Lewicka, D.; Rhee, G.S.; Sprague, J.E.; Nichols, D.E. (1996) Reinforcing effects of certain serotonin-releasing amphetamines derivatives. Pharmacol. Biochem. Behav. 53, 99-105.
Mazzola-Pomietto, P.; Aulakh, C.S.; Huang, S.J.; Murphy, D.L. (1996) Repeated administration of meta-chlorophenylpiperazine or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) produces tolerance to its stimulatory effect on adrenocorticotropin hormone but not prolactin or corticosterone secretion in rats. J. Pharmacol. Exp. Ther. 279, 782-789.
McGinty, J.F. (1995) Introduction to the role of excitatory amino acids in the actions of abused drugs: a symposium presented at the 1993 annual meeting of the College on problems of Drug Dependence. Drug Alcohol Depend. 37, 91-94.
Meana, J.J.; Barturen, F. (1995) (eds). Psicoestimulantes: cocaína, anfetaminas y xantinas. Instituto Deusto de Drogodependencias. Bilbao.
Miller, D.B.; O’Callaghan, J.P. (1995) The role of temperature, stress and other factors in the neurotoxicity of the substituted amphetamines, 3,4-methylenedioxy methamphetamine and fenfluramine. Mol. Neurobiol. 11, 177-192.
Moorman, J.M.; Leslie, R.A. (1996) p-chloroamphetamine induces c-fos in rat brain: a study of serotonin 2A/2C receptor function. Neuroscience, 72, 129-139.
Nichols, D.E. (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J. Psychoactive Drugs, 18, 305-313.
Nishisawa, S.; Mzengeza, S.; Diksic, M. (1999) Acute effects of 3,4-methylenedioxymethamphetamine on brain serotonin synthesis in the dog studied by positron emission tomography. Neurochem. Int. 34, 33-40
Oberlender,R.; Ramarchandrab, P.V.; Johnson, M.P.; Huang, X.; Nichols, D.E. (1995) Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines J. Med. Chem. 38: 3593-3601.
Pineda-Ortiz, J.; Torrecilla-Sesma, M. (1999) Mecanismos neurobiológicos de la adicción a drogas. Trastornos adictivos, 1, 13-21.
Ramamoorthy, S.; Blakely, R.D. (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psichostimulants. Science, 285, 763-766.
Ricaurte, G.A.; Katz, J.L.; Martello, M.B. (1992) Lasting effects of (±) 3,4-methylenedioxymethamphetamine on central serotoninergic neurons in non-human primates. J. Pharmacol. Exp. Ther. 261, 616-622
Sallés, J; Dierssen, M. (1995) Neurobiología del abuso de anfetaminas y sustancias derivadas. En Meana, J.J. y Barturen, F. (eds) «Psicoestimulantes: cocaína, anfetaminas y xantinas». Instituto Deusto de Drogodependencias. Bilbao. pp 4-85
San, L. (1993) Dependencia de anfetaminas. En Casas, M. Gutierrez, M; San, L. Adicción a psicofármacos. Citran. Barcelona. pp 261-281.
Sonsalla, P.K. (1995) The role of N-methyl-D-Aspartate receptor in dopaminergic neuropathology produced by the amphetamines. Drug Alcohol Depend. 37, 101-105
Toru, M.; Kurumaji, A.; Ishimaru, M. (1994) Excitatory amino acids: implications for psychiatric disorders research. Life Sci. 55, 1683-1699.
Wang, J.Q.; McGinty, J.F. (1995) Differential effects of D1 and D2 dopamine receptor antagonists on acute amphetamine or methamphetamine induced up regulation of zif/268 mRNA expression in rat forebrain. J. Neurochem. 65, 2706-2715.
Wang, J.Q.; Smith, A.J.; McGinty, J.F. (1995) A single injection of amphetamine and metamphetamine induces dynamic alterations in c-fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain. Neuroscience, 68, 83-95.
Weissman, A.D.; Caldecott-Hazard, S. (1995) Developmental neurotoxicity to methamphetamines. Clin. Exp. Pharmacol. Physiol. 22, 372-374.
Wichems, C.H.; Hollingsworth, C.K.; Bennet, B.A. (1995) Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechamism of release. Brain Res. 695, 10-18.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
